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Objectives: The present study aims to compare the diagnostic efficacy of MR, 18F-FDG
PET/CT, and 18F-FDG PET/MR for the local detection of early-stage extranodal natural
killer/T-cell lymphoma, nasal type (ENKTL).
Patients and Methods: Thirty-six patients with histologically proven early-stage ENKTL
were enrolled from a phase 2 study (Cohort A). Eight nasopharyngeal anatomical regions
from each patient were imaged using 18F-FDG PET/CT and MR. A further nine patients
were prospectively enrolled from a multicenter, phase 3 study; these patients underwent
18F-FDG PET/CT and PET/MR after a single 18F-FDG injection (Cohort B). Region-
based sensitivity and specificity were calculated. The standardized uptake values (SUV)
obtained from PET/CT and PET/MR were compared, and the relationship between the
SUV and apparent diffusion coefficients (ADC) of PET/MR were analyzed.
Results: In Cohort A, of the 288 anatomic regions, 86 demonstrated lymphoma
involvement. All lesions were detected by 18F-FDG PET/CT, while only 70 were detected
by MR. 18F-FDG PET/CT exhibited a higher sensitivity than MR (100% vs. 81.4%,
χ2 = 17.641, P < 0.001) for local detection of malignancies. The specificity of 18F-
FDG PET/CT and MR were 98.5 and 97.5%, respectively (χ2 = 0.510, P = 0.475).
The accuracy of 18F-FDG PET/CT was 99.0% and the accuracy of MR was 92.7%
(χ2 = 14.087, P < 0.001). In Cohort B, 72 anatomical regions were analyzed. PET/CT
and PET/MR have a sensitivity of 100% and a specificity of 92.5%. The two methods
were consistent (κ = 0.833, P < 0.001). There was a significant correlation between
PET/MR SUVmax and PET/CT SUVmax (r = 0.711, P < 0.001), and SUVmean
(r = 0.685, P < 0.001). No correlation was observed between the SUV and the ADC.
Conclusion: In early-stage ENKTL, nasopharyngeal MR showed a lower sensitivity and
a similar specificity when compared with 18F-FDG PET/CT. PET/MR showed similar
performance compared with PET/CT.
Keywords: 18F-FDG, PET/MR, PET/CT, MR, extranodal NK/T-cell lymphoma, nasal-type
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INTRODUCTION
Extranodal natural killer/T-cell lymphoma, nasal type (ENKTL)
is a rare and distinct entity of extranodal non-Hodgkin
lymphoma (NHL), which is more prevalent in Asia (1–3). ENKTL
displays highly aggressive behavior with extensive local spread
and poor prognosis. Since almost 75% of patients present early-
stage I or II disease within the nasal cavity and adjacent sites
(4), radiotherapy is routinely performed on these patients (5).
Therefore, it is very important to define the extent of tumor
invasion and observe regional structures in ENKTL to assess its
complexity in the nasal cavity and surrounding areas (6–8).
Almost all cases of ENKTL are 18F-FDG avid (9, 10), and
the efficacy of 18F-FDG PET/CT has been confirmed in the
assessment of ENKTL (11–14). Magnetic resonance (MR)
with diffusion-weighted imaging (DWI) has been reported
to better distinguish the extent of tumor invasion in early-
stage ENKTL owing to its ability to reveal fine anatomical
details (15); however, the technique still warrants further
validation. The combinational modality of PET/CT and MR
is commonly recommended in patients with ENKTL for
pretreatment evaluation and radiotherapy planning in National
Comprehensive Cancer Network (NCCN) Guidelines (16).
Whole-body 18F-FDG PET/MR was recently introduced
into clinical imaging and offers a combination of metabolic
information (provided by 18F-FDG PET) with a high soft tissue
contrast anatomical resolution (provided by morphological
MR). 18F-FDG PET/MR also provides an indirect assessment of
cell density through use of DWI. PET/MR images demonstrate
more discernible performance for mapping tumor invasion,
particularly intracranial invasion, compared with PET/CT,
and it is also effective in distinguishing retropharyngeal
nodal metastases from adjacent nasopharyngeal tumors
using a lower level of radiation (17). To our knowledge, the
diagnostic efficacy of PET/MR in early-stage ENKTL has never
been assessed.
In the present study, we investigated the efficacy of MR
(including DWI), 18F-FDG PET/CT, and 18F-FDG PET/MR
scans for detection of local lesions in patients with early-stage
ENKTL and further explored if PET/MR is a viable alternative
to the conventional PET/CT plus MR modality for pretreatment
evaluations using a lower level of radiation.
MATERIALS AND METHODS
Patients
From March 2014 to July 2017, 36 patients enrolled in a
phase 2 study and an expansion cohort (NCT02825147,
retrospectively analyzed) with newly diagnosed ENKTL in China
underwent whole-body 18F-FDG PET/CT and nasopharyngeal
MR (including DWI) within 14 days prior to the start of
treatment (Cohort A). All patients had stage I or II disease.
From May 2018 to November 2018, a further nine patients
were prospectively enrolled from a multicenter, phase 3 study
(NCT02631239) being conducted in China. These patients
underwent whole-body 18F-FDG PET/CT followed by head and
neck PET/MR (including DWI) before treatment with a single
18F-FDG injection (Cohort B). Patient diagnosis was defined
using the World Health Organization classification (18). The
study was approved by the Ethics Committee of Rui Jin Hospital,
Shanghai Jiao Tong University, School of Medicine. Informed
consent was obtained from patients in accordance with the
Declaration of Helsinki.
Examinations
18F-FDG PET/CT was performed using a Discovery VCT16
system (GE Healthcare, United States). The 18F-FDG tracer
was manufactured automatically using the tracer synthesis
system of the Tracerlab FXF-N (GE Healthcare), with a
radiochemical purity >95%. Patients were required to fast
for at least 6 h before imaging, and the serum glucose
concentration was maintained at <7.0 mmol/L. A whole-body
image was obtained 1 h after intravenous administration of
5–6 MBq of 18F-FDG per kilogram of body weight. CT was
performed on the same scanner (120–180 mA and 140 kV). PET
data was reconstructed using a three-dimensional attenuation-
weighted ordered subset expectation maximization algorithm
(Two iterations, 21 subsets, 256 × 256 matrix) and Gaussian
smoothing kernel (full width at half maximum = 6 mm). MR
imaging was performed using the 1.5-T system (Sigma, GE
Healthcare, United States). All patients underwent an axial T1-
weighted spin-echo sequence [repetition time (TR)/echo time
(TE), 1709 ms/28 ms] and an axial T2-weighted fast spin-
echo sequence (TR/TE, 4,800 ms/82 ms). DWI data were
collected with tri-directional diffusion gradients (b values = 50,
800 s/mm2).
PET/MR was performed using an integrated PET/MR system
(Biograph mMR; Siemens Healthineers, Erlangen, Germany).
The PET/MR system was based on a 3.0-T MR system
with a 16-channel radiofrequency head/neck coil. MR imaging
was performed simultaneously with PET data acquisition
with a total acquisition time of 15 min. The magnetic
resonance imaging (MRI) protocol comprised the following
sequences: high-resolution 3D magnetization-prepared rapid
acquisition with gradient echo (3D-T1-MPRAGE) sequence
(TR/TE, 4600 ms/66 ms); axial and coronal two-dimensional T2-
weighted imaging with fat saturation (TR/TE, 740 ms/15 ms);
and apparent diffusion coefficient (ADC) parametric maps based
on single-shot DWI (b values = 50, 800 s/mm2). PET data was
reconstructed as described above.
Image Analysis
In Cohort A, MR images were analyzed by two radiologists
with knowledge of histological diagnosis; both radiologists were
blinded to the PET/CT results. PET/CT images were analyzed by
two nuclear medicine physicians with knowledge of histological
diagnosis; both physicians were blinded to the MR results. In
Cohort B, PET/CT and PET/MR images were analyzed by two
nuclear medicine physicians and two radiologists with knowledge
of histological diagnosis; any differences in opinion were resolved
by consensus. Eight nasopharyngeal anatomical regions in each
patient, including nasal, nasopharynx, oropharynx/throat, sinus,
bone, epidermal/soft tissue, eyelids/contents, and cervical lymph
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nodes, were imaged and assessed. A lesion with 18F-FDG uptake
that was greater than normal radioactivity background or normal
liver tissue and that was unrelated to the physiological site
of tracer uptake or excretion was rated positive. MR images
were assessed in terms of tumor mass enhancement, signal
characteristics, location, local extension, bony destruction, soft
tissue invasion, and regional lymph node involvement.
In Cohort B, the PET criteria for PET/MR were identical
to the criteria for PET/CT. T1-weighted and T2-weighted MRI
were used to anatomically locate the position of abnormal tracer
accumulation in 18F-FDG PET. If DWI showed a high signal,
and the corresponding ADC map showed a low value, the lesion
was considered positive (19). Because false-positive findings in
the lymph nodes have been previously reported with DWI, only
lymph nodes with restricted diffusion and a long axis diameter
of >1 cm were considered positive (20). A region of interest
(ROI) analysis was performed based on 18F-FDG-PET images
fused with images obtained from axial DWI. For each lesion, the
maximum, mean, and peak standardized uptake value (SUVmax,
SUVmean, and SUVpeak, respectively) of 18F-FDG PET/CT and
18F-FDG PET/MR, and the minimum and mean ADC (×10−6
mm2/s) of PET/MR were measured. ADC was measured on the
section that showed the maximum transverse lesion diameter.
Biopsy, additional imaging studies, and clinical follow-up were
used as the gold standard to confirm lymphoma involvement
in both cohorts.
Statistical Analysis
To determine the diagnostic value of MR, 18F-FDG PET/CT,
and 18F-FDG PET/MR, lesion-based sensitivity, specificity, and
accuracy were calculated. Differences in sensitivity and specificity
were determined using McNemar’s test. Spearman’s correlation
coefficient (r) was used to assess the relationship between the SUV
of 18F-FDG PET/MR and 18F-FDG PET/CT. The relationship of
the SUV and the ADC of 18F-FDG PET/MR was also assessed.
A P-value of <0.05 was considered statistically significant. All
statistical tests were performed using SPSS Statistics 23.0 (SPSS
Inc., Chicago, IL, United States).
RESULTS
Patient Characteristics
In Cohort A, 18F-FDG PET/CT and nasopharyngeal MR were
performed in 36 patients (Table 1). The median age was 49.5 years
(age range, 13.0–72.0 years). In terms of clinical prognostic index,
18 (50.0%), 16 (44.4%), and 2 (5.6%) patients were defined
as low-, intermediate-, and high-risk, respectively, using the
prognostic index of natural killer lymphoma. The median interval
between the beginning of PET/CT and MR was 3.5 days (range,
0–14 days). The median follow-up duration was 36.5 months
(range, 7–57 months).
In Cohort B, nine patients (six males and three females), with
a median age of 44.0 years (range, 28.0–71.0 years) were analyzed
(Table 2). The median follow-up duration was 18 months (range,
16–22 months). All patients had stage I or II disease within
the nasal cavity and surrounding tissues. Cervical nodes were
TABLE 1 | Clinical characteristics of the patients in Cohort A (n = 36).










Involvement of regional lymph nodes
Yes 7 19.4
No 29 80.6
Prognostic index of natural killer lymphoma (PINK)
Low-risk (0) 18 50.0
Intermediate-risk (1) 16 44.4
High-risk (2–4) 2 5.6
TABLE 2 | Clinical characteristics of the patients in Cohort B (n = 9).










Involvement of regional lymph nodes
Yes 4 44.4
No 5 55.6
Prognostic index of natural killer lymphoma (PINK)
Low-risk (0) 7 77.8
Intermediate-risk (1) 2 22.2
High-risk (2–4) 0 0
involved in four patients. The interval between the beginning
of PET/CT and PET/MR was 42.9 ± 20.9 min (range, 25.0–
79.0 min).
18F-FDG PET/CT Scanning Versus MR
In Cohort A, 288 sites in 36 patients were analyzed. There
was at least one lesion with intense 18F-FDG uptake in all 36
patients, giving a patient-based detection rate of 100%, while
MR detected at least one lesion in 31 out of 36 patients, giving
a patient-based detection rate of 86.1%. The characteristics of
18F-FDG PET/CT and MR are illustrated in Figure 1. Of the
288 anatomical regions, 86 were positive for malignancy. 18F-
FDG PET/CT detected all the malignant lesions, while MR
detected 70 of the malignant lesions (sensitivity: 100% vs.
81.4%, χ2 = 17.641, P < 0.001). The specificities of 18F-FDG
PET/CT and MR were 98.5 and 97.5% (χ2 = 0.510, P = 0.475),
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FIGURE 1 | A 42-year-old man with ENKTL presented with nasal obstruction. (A) Axial section T1WI shows an isointense soft-tissue mass (arrow) in the nasal cavity
and nasal septum. (B) Axial section T2WI shows the abnormal tissue as heterogeneously hyperintense. (C) Contrast-enhanced T1WI showing heterogeneous
enhancement of tumor tissues. (D) DWI shows limited lesion diffusion. (E) Axial CT shows a soft tissue mass and nasal septum destruction. It was difficult to
distinguish the soft tissue mass from inflammatory thickening of the mucosa in the right maxillary sinus using CT. (F) 18F-FDG PET/CT shows high glucose
metabolism in the nasal cavity lesion, while low glucose metabolism is observed in the mucosa of the right maxillary sinus. The nasal cavity lesion was suspicious of
tumor in both MRI and PET/CT, while the right maxillary sinus lesion was suspicious of inflammation.
TABLE 3 | The efficacy of 18F-FDG PET/CT and 18F-FDG PET/MR in early-stage ENKTL in different nasopharyngeal anatomical regions.
Method No. of cases Sensitivity (%) Specificity (%) Accuracy (%)
Nasal cavity PET/CT 29 29/29 (100) 7/7 (100) 36/36 (100)
MR 29 21/29 (72.4) 7/7 (100) 28/36 (77.8)
Nasopharyngeal PET/CT 19 19/19 (100) 16/17 (94.1) 35/36 (97.2)
MR 19 18/19 (94.7) 17/17 (100) 35/36 (97.2)
Oropharynx and throat PET/CT 13 13/13 (100) 22/23 (95.7) 35/36 (97.2)
MR 13 10/13 (76.9) 22/23 (95.7) 32/36 (88.9)
Sinus PET/CT 8 8/8 (100) 28/28 (100) 36/36 (100)
MR 8 7/8 (87.5) 28/28 (100) 35/36 (97.2)
Bone PET/CT 2 2/2 (100) 34/34 (100) 36/36 (100)
MR 2 2/2 (100) 34/34 (100) 36/36 (100)
Epidermal and soft tissue PET/CT 5 5/5 (100) 31/31 (100) 36/36 (100)
MR 5 4/5 (80) 31/31 (100) 35/36 (97.2)
Eyelids and contents PET/CT 3 3/3 (100) 33/33 (100) 36/36 (100)
MR 3 3/3 (100) 33/33 (100) 36/36 (100)
Cervical lymph nodes PET/CT 7 7/7 (100) 28/29 (96.6) 35/36 (97.2)
MR 7 5/7 (71.4) 25/29 (86.2) 30/36 (83.3)
ENKTL, extranodal natural killer T-cell lymphoma, nasal type.
Frontiers in Oncology | www.frontiersin.org 4 October 2020 | Volume 10 | Article 576409
fonc-10-576409 October 8, 2020 Time: 18:48 # 5
Guo et al. PET/MR and PET/CT for ENKTL
respectively. The accuracy of 18F-FDG PET/CT was 99.0%, and
the accuracy of MR was 92.7% (χ2 = 14.087, P < 0.001).
The two methods were consistent (κ = 0.927, P < 0.001). The
detection efficiencies of nasopharyngeal 18F-FDG PET/CT and
MR in patients with ENKTL in different regions are shown
in Table 3.
18F-FDG PET/CT revealed superior sensitivity over MR
in 16 out of 86 lesions, including 5 lesions without any
suspicious lesions in MR and 11 with lesion misinterpretations
(Figure 2). The false negatives obtained using MR were mostly
in the nasal cavity (8 out of 29, 27.6%) and oropharynx
(3 out of 13, 23.1%). When sinusitis concurred, lymphoma
was missed by MR.
There were three false-positive lesions when using 18F-
FDG PET/CT. Two were caused by inflammation of cervical
lymph nodes, which was confirmed at clinical follow up. The
third was caused by physiological uptake in the oropharynx
with an asymmetrical 18F-FDG concentration, which was later
confirmed negative using a laryngoscope. All three lesions
that were misrecognized by 18F-FDG PET/CT were negative
on MR. However, five false-positive lesions were observed by
MR. Four of these lesions were normal cervical lymph nodes
with a high signal in DWI, while one was caused by nasal
mucosal inflammation, which was confirmed as benign during
clinical follow-up.
Diagnostic Efficacy of 18F-FDG PET/CT
and 18F-FDG PET/MR
In Cohort B, the diagnostic efficacy of 18F-FDG PET/CT and
PET/MR is shown in Table 4. Both PET/CT and PET/MR
had high sensitivity (100% for both) and specificity (92.3%
for both). There were three false-positive cases detected using
PET/CT, which were in the nasopharynx, oropharynx, and
cervical lymph nodes, respectively. These lesions still had
mild 18F-FDG uptake during follow-up after chemotherapy,
while other lymphoma lesions had disappeared, and all clinical
lymphoma-related indicators improved, suggesting that the
three sites were false positive. Since all cervical lymph nodes
demonstrate a high signal with DWI, we combined lymph
node morphology, ADC results, and FDG uptake to determine
whether the lymph nodes were involved. However, there
were still three false-positive lesions observed when using
PET/MR, one in the cervical lymph nodes and the other two
in the nasopharynx and the nasal cavity (Figure 3). A test
for consistency in the diagnoses provided by PET/MR and
PET/CT was conducted using McNemar’s test. The results
FIGURE 2 | A 66-year-old man with ENKTL. T1WI (A) and T2WI (B) show bilateral thickening in the nasal mucosa with isointensity. (C) Contrast-enhanced T1WI
show bilateral heterogeneous enhancement in the nasal mucosa. (D) DWI shows limited lesion diffusion of bilateral nasal mucosa. (E) Axial CT shows a small soft
tissue mass (arrow) in the right nasal cavity. (F) 18F-FDG PET/CT shows high glucose metabolism in the small soft tissue mass, which was an ENKTL lesion, but this
was non-specific in MR.
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TABLE 4 | Diagnostic efficacy of 18F-FDG PET/MR and 18F-FDG PET/CT in ENKTL.
Pos Neg Total Sen (95% CI), % Spe (95% CI), %
PET/MR Pos 32 3 35 100 (100)% 92.5 (84.3, 100)%
Neg 0 37 37
Total 32 40 72
PET/CT Pos 32 3 35 100 (100)% 92.5 (84.3, 100)%
Neg 0 37 37
Total 32 40 72
ENKTL, extranodal natural killer T-cell lymphoma, nasal type; Pos, number of positive examinations; Neg, number of negative examinations; Sen, sensitivity; Spe, specificity;
CI, confidence interval.
suggest that the two methods were highly consistent (κ = 0.833,
P < 0.001).
The Correlation of SUVmax and
SUVmean Between 18F-FDG PET/MR
and 18F-FDG PET/CT
Among the 72 regions, a total of 32 regions were confirmed
as malignant. We compared the SUV values (including
SUVmax and SUVmean) in these lesions between PET/MR
and PET/CT. There were no significant differences in SUVmax
(t = −0.127, P = 0.900) or SUVmean (t = −1.202, P = 0.238)
between PET/MR and PET/CT. Quantitative analysis and
correlation analysis of the lesions are shown in Figure 4.
There was a significant positive correlation in SUVmax between
PET/MR (14.8 ± 8.6) and PET/CT (15.0 ± 9.8) (r = 0.711,
P < 0.001). SUVmean also showed a positive correlation with
PET/MR (8.0 ± 4.0) and PET/CT (8.9 ± 5.8) (r = 0.685,
P < 0.001).
The Correlation Between ADC and SUV
in PET/MR
All of the 32 18F-FDG-avid lesions exhibited restricted diffusion
on DWI. The ADC value is an important quantitative indicator in
DWI. In the 32 lesions, the mean ADCmin, ADCmean, SUVmax,
SUVmean, and SUVpeak are illustrated in Table 5. We analyzed
the correlation between the SUV and the ADC in 18F-FDG
PET/MR. Pearson’s correlation analysis showed no significant
correlation between the SUV and the ADC.
DISCUSSION
Accurate staging plays an important role in the development
of treatment plans for patients with ENKTL. In clinical
practice, PET is necessary for whole-body detection of
lymphoma involvement, while MR is required for local
radiotherapy planning. To the best of our knowledge,
the present study is the first to compare the efficacy of
nasopharyngeal MR and nasopharyngeal 18F-FDG PET/CT in
early-stage ENKTL in one cohort. This is also the first study
to evaluate the role of PET/MR in this particular subtype
of lymphoma.
In the present study, the nasal cavity and surrounding
lesions were 18F-FDG-avid. PET exhibited high efficacy in cases
with normal extranodal sites and normally sized lymph nodes,
which is consistent with the results of previous studies (21–24).
Our results indicate that 18F-FDG PET/CT is more efficacious
than MR for lesion detection. Although MR may miss true
lesions, including those in the nasal cavity or oropharynx
that have no obvious morphological or signal changes; and
may have false positivity (20), MR is still important for
radiotherapy planning.
Integrated PET/MR is a new imaging modality with potential
applications in oncology, such as lymphoma staging and
treatment response evaluation. Giraudo et al. (25) compared
18F-FDG PET/CT and 18F-FDG PET/MR (including DWI) in
the assessment of 34 patients with lymphoma. The sensitivity
of PET/CT and PET/MR were 82.1 and 100%, respectively,
while the specificity of both techniques was 100%. Four lesions
were false negative in PET/CT. Our results show a sensitivity
of 100% and a specificity 92.5% with both PET/CT and
PET/MR. The relatively lower specificity of PET/MR in our
study compared with Giraudo et al.’s study may be related
to the characteristics of DWI. Since all cervical lymph nodes
are high-signal in DWI (20), we considered multiple factors,
including lymph node morphology, the ADC, and 18F-FDG
uptake, to determine whether the lymph nodes are involved
and to reduce incidence of false-positive results; however,
three false-positive cases were still observed. The sensitivity of
PET/CT in our study is higher than the sensitivity observed
in Giraudo et al.’s study, which may be related to patient
selection. The four false-negative results in their study were
extranodal marginal zone B-cell lymphoma of mucosa-associated
lymphoid tissue (MALT), which is an indolent lymphoma
with poor 18F-FDG uptake, resulting in decreased sensitivity.
DWI is considered superior in some indolent NHL subtypes
(e.g., MALT lymphoma), which are frequently not 18F-FDG-
avid. The patients enrolled in the present study were recruited
from two prospective trials; all patients had stage I and
II ENKTLs, which retained consistency and homogeneity in
the study cohort.
The interval from the time of FDG administration to the time
of imaging has an effect on the SUV (26). Hamburg et al. (27)
found that the average time to reach 95% of the FDG plateau
value was approximately 5 h in patients with lung carcinoma.
The interval between the beginning of PET/CT and PET/MR was
42.9 ± 20.9 min in our study, so there may be a difference in
the SUV. Other factors, such as MR-based attenuation correction
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FIGURE 3 | A 61-year-old man with ENKTL. (A) T2WI shows mild thickening of the nasopharynx and left nasal cavity mucosa (arrow) with hyperintensity. (B) DWI
shows limited diffusion of the lesion. (C) PET/MR shows mild 18F-FDG uptake (SUVmax is 2.6, while the SUVmax of the reference liver is 2.3) and hyperintensity of
T2WI of the lesion with suspected malignancy. (D) CT shows mild thickening of the nasopharynx and left nasal cavity mucosa. (E) 18F-FDG PET/CT shows mild
18F-FDG uptake in the nasopharynx (SUVmax is 1.9, while the SUVmax of the reference liver is 2.4), suspected as physiological. (F) There was still mild 18F-FDG
uptake in the nasopharynx during follow-up. The patient did not show any sign of relapse after 42 months. This lesion was confirmed to be physiological in terms of
its uptake, and was false-positive by PET/MR.
FIGURE 4 | (A) The relationship of the SUVmax between PET/MR and PET/CT. (B) The relationship of the SUVmean between PET/MR and PET/CT. SUVmax,
maximum standardized uptake value; SUVmean, mean standardized uptake value.
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TABLE 5 | The relationship between the ADC and the SUV in PET/MR.
SUV Value ADC Value r P-value
SUVmax 14.8 ± 8.6 ADCmin 303.9 ± 226.8 −0.171 0.351
SUVmax 14.8 ± 8.6 ADCmean 722.3 ± 272.0 −0.083 0.650
SUVmean 8.0 ± 4.0 ADCmin 303.9 ± 226.8 0.03 0.869
SUVmean 8.0 ± 4.0 ADCmean 722.3 ± 272.0 −0.216 0.236
SUVpeak 11.3 ± 6.4 ADCmin 303.9 ± 226.8 −0.140 0.443
SUVpeak 11.3 ± 6.4 ADCmean 722.3 ± 272.0 −0.130 0.480
ADC, apparent diffusion coefficients; SUV, standardized uptake value.
and CT-based attenuation correction, may also have an effect
on SUV (28). Therefore, there is no consensus on whether the
SUV with PET/MR is higher or lower compared with PET/CT
(28, 29). Drzezga et al. (29) reported that the SUVmean of
lesions in PET/CT was greater than that of PET/MR, but the
correlation between the two values was strong. Atkinson et al.
(30) also showed a significant positive correlation between the
SUVmax of PET/MR and the SUVmax of PET/CT. Many studies
(28–30) are in agreement that the two methods demonstrate
a good level of consistency. As a result, PET/MR may have
a similar effect as PET/CT in terms of staging and efficacy
evaluation. In the present study, we noticed no discrepancies in
the SUV between PET/CT and PET/MR, which is consistent with
previous studies.
The SUV reflects tumor glucose metabolism and tumor
malignancy, while the ADC reflects the diffusion limitations of
tumor cells and tissues. Both parameters are used to distinguish
malignant lesions from non-malignant lesions. The relationship
between the SUV and the ADC is interesting. The SUV and
the ADC were negatively correlated in a previous study (31),
while another study (32) did not identify a correlation between
the ADC and the SUVmax in NHL in a comparative study.
In the latter study (32), PET and MR were performed using
different machines. Integrated PET/MR is useful to study the
relationship between the SUV and the ADC and minimizes the
error introduced by using different machines. Studies (30, 33)
used integrated PET/MR to study different subtypes and stages
of lymphoma, no correlation between the ADCmin and the
SUVmax was observed. The present study used a consistent and
homogeneous cohort of stage I and II ENKTL; no correlation was
observed between ADCmin and SUVmax. The lack of correlation
may indicate that their measures were reflective of two different
physiologic qualities: metabolism (FDG) and cellular density
(ADC). The relationship between glucose metabolism and cell
density in ENKTL is undetermined and requires clarification
with a large sample size. The lack of correlation in our study
may be attributed to the generally recognized heterogeneity of
tumor tissue (34). Finally, DWI and ADC values may have
varied due to signal loss and motion artifacts in the neck
region as a result of respiration and the arterial pulse, which
is consistent with previous research (35). Despite the absence
of a correlation between the SUV and ADC, we believe that
DWI should be part of PET/MR protocols for lymphomas,
since it has already demonstrated good diagnostic performance
for this disease.
One limitation of the present study is that not all lesions
(except of the primary site) that were classified as malignant
underwent biopsy and pathological confirmation. Biopsies of
every suggestive lesion are neither ethical nor recommended in
routine clinical practice. Non-malignant lesions, such as focal
inflammation, may be falsely regarded as positive. Another
limitation of the present study is the small sample size used (20).
However, to the best of our knowledge, this is the largest study to
assess ENKTL independently, even in countries where this type
of tumor is considered more prevalent. At the same time, due
to the scarcity of PET/MR, research in this area is rare. Further
large, multicenter, prospective studies are required to validate
the diagnostic and staging efficacy of PET/MR for early-stage
ENKTL.
CONCLUSION
In conclusion, 18F-FDG PET/CT is more effective than MR for
detection of local lesions in patients with early-stage ENKTL.
PET/MR showed similar performance when compared with
PET/CT.
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